Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster ...

Two leading glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and type 2 diabetes – Novo Nordisk A/S’s semaglutide (Wegovy/Ozempic) and Eli Lilly and Co.’s tirzepatide (Mounjaro/Zepbound) ...

Company earnings reported early in the quarter showed growth remained strong, with improved manufacturing volumes and steady ...

Compounding pharmacies that offer their own homebrew GLP-1 drugs are the new designer smoke shops: Illegal, unsafe, and ...

So here are some items of interest. Have a great day, everyone. … Hims & Hers Health plans to sell compounded versions of Novo Nordisk’s popular weight loss drug Wegovy to patients in certain ...

The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive. Indeed, the ...

Novo Nordisk A/S’s obesity shot Wegovy also prevents strokes, heart attacks and death. The price of those benefits is far ...

Ozempic and similar weight-loss drugs can lower the risk of heart attack, stroke, kidney and liver disease, and even increase ...

The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise ...

Pharmacist Mark Mikhael has lost 50 pounds over the past 12 months. He no longer has diabetes and finds himself “at my ideal ...

Plus: GLP-1 drugs like Ozempic have potential to treat cancer, COVID-19, heart disease, and many other diseases.

Company is investing $2.8bn in two Irish plants to produce its in-demand weight loss drugs and a new Alzheimer’s therapy ...